重症COVID-19患者血栓栓塞、高凝状态与抗磷脂抗体:强化抗凝前后对比研究
该回顾性前后对照研究在三级ICU纳入两批重症COVID-19男性机械通气患者,比较强化预防性抗凝策略前后(队列1 n=12,低分子肝素129±53 U/kg/24h;队列2 n=14,200±82 U/kg/24h,p=0.04)的血栓事件、血栓弹力图、炎症标志物及抗磷脂抗体。队列1中50%发生肺栓塞,多数存在高凝,>80%可检出抗磷脂抗体。队列2肺栓塞降至21%(p=0.22,未达显著),纤维蛋白原降低(6.3±2.5 vs 8.7±2.0,p=0.02),纤维蛋白原依赖性血栓弹力图高凝减低(p<0.001),炎症标志物降低。提示强化抗凝可能改善高凝与炎症,但肺栓塞获益需前瞻性验证。
要点
- 重症COVID-19男性机械通气患者中,低分子肝素129±53 U/kg/24h预防下50%发生肺栓塞,多数血栓弹力图提示高凝,>80%可检出抗磷脂抗体。
- 强化低分子肝素至200±82 U/kg/24h(p=0.04 vs 队列1)后肺栓塞发生率21%(p=0.22,未达统计学显著)。
- 强化抗凝后纤维蛋白原由8.7±2.0降至6.3±2.5(p=0.02),纤维蛋白原依赖性血栓弹力图高凝减低(p<0.001),炎症标志物降低。
- 该研究为回顾性前后对照、单中心、样本量小(12 vs 14),强化抗凝的临床获益不能据此确立。
适用人群与场景
- 三级ICU收治的重症COVID-19患者,两批横断面队列:强化预防性抗凝策略前(队列1,n=12)与后(队列2,n=14)。
- 原文明确所有患者均为男性且接受机械通气。
- 原文未提及纳入/排除标准细节及院前或急诊场景。
诊断标准与关键阈值
- 血栓弹力图(Tem International GmbH, Munich, Germany)用于评估高凝状态,原文未给出具体高凝判定阈值。
- 抗磷脂抗体于血浆中检测,原文未给出阳性判定界值。
处置流程与药物剂量
- 队列1接受低分子肝素129±53 U/kg/24h(预防剂量),队列2接受强化低分子肝素200±82 U/kg/24h(p=0.04 vs 队列1)。
- 原文未提及低分子肝素具体药名、给药途径、频次、疗程及抗凝目标值。
- 原文未提及其他抗凝药物或剂量调整方案。
红旗征与不能漏的情况
- 重症COVID-19机械通气患者中肺栓塞常见(队列1为50%,队列2为21%),需警惕血栓栓塞并发症。
- 多数患者血栓弹力图提示高凝,>80%可检出抗磷脂抗体,原文未提及针对这些发现的特定紧急处理。
研究设计与关键结果
- 干预:队列1低分子肝素129±53 U/kg/24h,队列2强化至200±82 U/kg/24h(p=0.04)。
- 主要结局:队列1肺栓塞50%,队列2为21%(p=0.22,未达统计学显著)。
- 关键次要结局:纤维蛋白原队列1 8.7±2.0 vs 队列2 6.3±2.5(p=0.02);纤维蛋白原依赖性血栓弹力图高凝减低(p<0.001);炎症标志物降低。
- 其他:队列1多数患者血栓弹力图高凝,>80%可检出抗磷脂抗体。
证据类型、等级与局限
- 证据类型:回顾性前后对照研究(原文Design: Retrospective)。
- 证据等级或推荐强度:原文未提及。
- 局限:单中心、样本量小(n=12与n=14)、回顾性设计、前后不同时期队列比较、未随机化;肺栓塞差异未达统计学显著;原文未报告不良事件。
对床旁实践的改变
- 提示重症COVID-19机械通气患者血栓栓塞及高凝常见,应考虑血栓弹力图等凝血功能监测及抗磷脂抗体检测(原文未给出监测频率)。
- 强化低分子肝素(200±82 U/kg/24h)在原文中与纤维蛋白原降低、纤维蛋白原依赖性高凝减低及炎症标志物降低相关,但肺栓塞下降未达统计学显著,不能据此常规推荐强化抗凝剂量。
- 适用人群:原文仅限男性机械通气重症COVID-19患者;不适用人群及常见陷阱原文未提及。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: To determine the prevalence of thrombotic events, functional coagulation tests, inflammatory biomarkers, and antiphospholipid antibodies before and after enhanced anticoagulation in critically ill coronavirus disease 2019 patients.
DESIGN: Retrospective.
SETTING: Tertiary intensive care unit.
PATIENTS: Two cross-sectional cohorts of ICU-treated coronavirus disease 2019 patients were included before (cohort 1, n = 12) and after (cohort 2, n = 14) enhanced prophylactic anticoagulation strategy.
INTERVENTIONS: Before and after study of enhanced anticoagulation.
MEASUREMENTS AND MAIN RESULTS: Thromboelastometry point-of-care coagulation tests were performed by thromboelastography (Tem International GmbH, Munich, Germany), standard blood tests were extracted from patient charts, and presence of antiphospholipid antibodies in plasma was measured. All patients were males on mechanical ventilation. In cohort 1 (low-molecular-weight heparin dose: 129 ± 53 U/kg/24 hr), 50% had pulmonary embolism, and thromboelastography analysis revealed hypercoagulation in a majority of patients and greater than 80% had detectable antiphospholipid antibodies. In the second cohort (enhanced low-molecular-weight heparin dose: 200 ± 82 U/kg/24 hr; p = 0.04 vs cohort 1), we found a nonsignificantly lower prevalence of pulmonary embolism (21%; p = 0.22), lower fibrinogen (6.3 ± 2.5 vs 8.7 ± 2.0; p = 0.02), reduced fibrinogen-dependent thromboelastography (p < 0.001), and lower inflammatory markers.
CONCLUSIONS: In these two cross-sectional cohorts of ICU-treated coronavirus disease 2019 patients, thromboembolic complications, hypercoagulation, and antiphospholipid antibodies were common. A more aggressive anticoagulation regime was associated with a reduction in inflammatory biomarkers including plasma fibrinogen and a reduction in fibrinogen-dependent hypercoagulation, as indicated by thromboelastography analyses.
参考来源
- van der Linden J, Almskog L, Liliequist A, et al. Thromboembolism, Hypercoagulopathy, and Antiphospholipid Antibodies in Critically Ill Coronavirus Disease 2019 Patients: A Before and After Study of Enhanced Anticoagulation. Crit Care Explor. 2020. PMID: 33364605. doi:10.1097/CCE.0000000000000308
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。